EUVIMEDEUVIMED entdecken
Crossref

Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger

Lateef Aliyu, Junneng Wen, Sonali Sunsunwal, Jinke Wu, Noam Greenshtein, Effram Wei, Parastoo Azadi, Robert Price, Michael Betenbaugh

Cell Systems · 2026-08 · 17 (8) · 101655

DOI: 10.1016/j.cels.2026.101655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Systems, 2026-08. Verfasst von Lateef Aliyu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Butyrylcholinesterase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: US Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed three mammalian expression platforms-human embryonic kidney (HEK293), Chinese hamster ovary (CHO), and HepG2 cells-for their ability to produce recombinant human butyrylcholinesterase (rHuBChE), a promising bioscavenger for organophosphate (OP) poisoning treatment. Key challenges remain in producing rHuBChE with a glycosylation profile similar to that of the native human plasma enzyme butyrylcholinesterase (HuBChE), which is critical for its stability and in vivo half-life. HEK293 cells showed the most promising results, prompting extensive glycoengineering targeting over ten glycosylation-related genes to optimize the glycan profile. This involved knocking out genes associated with fucosylation, enhancing sialylation, and reducing glycan branching. Glycan analysis revealed a substantial reduction in aberrant glycan structures, improved sialylation, and a glycoprofile closely resembling that of plasma-derived HuBChE. These comprehensive modifications to glycosyltransferases and nucleotide sugar donor levels are expected to enhance pharmacokinetics and reduce immunogenicity, positioning rHuBChE as a viable candidate for further preclinical and clinical development against OP poisoning and other medical emergencies. A record of this paper's transparent peer review process is included in the supplemental information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ButyrylcholinesteraseHumansAnimalsGlycosylationRecombinant ProteinsCHO CellsHEK293 CellsCricetulusHep G2 CellsProtein EngineeringPolysaccharides

Stichwörter der Autor:innen

CRISPR-Cas9 genome editingglycoengineeringglycosylation profilinghost cell engineeringmammalian expression systemsmetabolic pathway engineeringrHuBChErecombinant human butyrylcholinesterase

Substanzen

ButyrylcholinesteraseRecombinant ProteinsPolysaccharides

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
  • Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA.
  • Technology Holding, Salt Lake City, UT, USA.
  • Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA. Electronic address: beten@jhu.edu.

Förderung

  • US Department of Defense

Zitieren

APA

Aliyu, L., Wen, J., Sunsunwal, S., Wu, J., Greenshtein, N., Wei, E., Azadi, P., Price, R., & Betenbaugh, M. (2026). Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger. Cell Systems, 17(8), 101655. https://doi.org/10.1016/j.cels.2026.101655

Vancouver

Aliyu L, Wen J, Sunsunwal S, Wu J, Greenshtein N, Wei E, et al. Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger. Cell Systems. 2026;17(8):101655. doi:10.1016/j.cels.2026.101655

BibTeX
@article{Aliyu2026,
  author = {Aliyu, Lateef and Wen, Junneng and Sunsunwal, Sonali and Wu, Jinke and Greenshtein, Noam and Wei, Effram and Azadi, Parastoo and Price, Robert and Betenbaugh, Michael},
  title = {Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger},
  journal = {Cell Systems},
  year = {2026},
  volume = {17},
  number = {8},
  pages = {101655},
  doi = {10.1016/j.cels.2026.101655}
}
Kostenlos starten →